CTi Biopharma Corp (CTIC)

5.710
-0.300(-4.99%)
Pre Market
5.860
+0.150(+2.63%)
- Real-time Data
  • Volume:
    6,277,210
  • Day's Range:
    5.675 - 6.225
  • 52 wk Range:
    1.430 - 7.800

CTIC Overview

Prev. Close
6.01
Day's Range
5.675-6.225
Revenue
14.62M
Open
6.03
52 wk Range
1.43-7.8
EPS
-1.21
Volume
6,277,210
Market Cap
653.11M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
4,923,450
P/E Ratio
-
Beta
-
1-Year Change
109.16%
Shares Outstanding
114,380,307
Next Earnings Date
Nov 14, 2022
What is your sentiment on CTi Biopharma?
or
Market is currently closed. Voting is open during market hours.

CTi Biopharma Corp News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

CTi Biopharma Corp Company Profile

CTi Biopharma Corp Company Profile

Employees
123

CTI BioPharma Corp. is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, IRAK1, FLT3 and CSF1R for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is conducting the Phase III PACIFICA study of pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions, such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), graft versus host disease (GvHD) and chronic lymphocytic leukemia (CLL) due to its inhibition of JAK2, IRAK1, FLT3 and CSF1R.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellSellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy
  • Rialzo a tre cifre percentuali da un momento all'altro
    0
    • cosa ti ha indotto a quel commento? cosa ti aspetti ora che hanno approvato il farmaco?
      0
  • This is Ready for a good run, bought for $2 I'm waiting for a run to the north, there are catalysts for the near future, with this breakthrough attempt it can go crazy.
    0
    • Best buy FDT/HOTBITwill jump very soon
      0
      • Are we going to have a big spike soon or a big pull back?¿
        0
        • take care guys of high price they are going to make offers soonest with 51mlln $ and the price will drop down
          0
          • Scrivi i tuoi pensieri su CTi Biopharma Corp
            0
            • Holding long and strong
              0
          • Hello Folks, is it possible CTIC outperform above?  Current Price US$3.49 Fair Value US$41.87 Found it on SimplyWall
            0
            • RDGL approval or denial by Jan 16 by the FDA for breakthrough designation for their tumor fighting drug
              0
              • RDGL 0.125 By 1/16/2021 FDA will provide a final decision to grant or deny their request for breakthrough designation.
                0
                • 30 novembre 2020 07:00 EST 30 novembre 2020 07:00 EST CTI BioPharma annuncia la pubblicazione dell'articolo Evidenziando i dati Pacritinib dallo studio PAC203 Phase 2 in Mielofibrosi nei progressi del sangue CTI BioPharma annuncia la pubblicazione dell'articolo Evidenziando i dati Pacritinib dallo studio PAC203 Fase 2 a Mielofibrosi nei progressi del sangue Scrivi i tuoi pensieri su CTi Biopharma Corp
                  0
                  • Ciao! Che ne pensi di CTIC andra' su come le attese?
                    0